Entries by paul

Biopromic awarded Medtech 4 Health grant from Vinnova

We are hapy to anounce that Biopromic, together with Volkan Ozenci from Karolinska Institute and Simon Atlin from Örebro Univeristy has been awarded a Medtech 4 health grant for development and evaluation of sample treatment platform for infectious disease immunoassaysIn this Project we aim to validate the SpeClean technology as a new standard treatment of […]

Ultrasensitive detection of lipoarabinomannan with plasmonic grating biosensors in clinical samples of HIV negative patients with tuberculosis

Ultrasensitive detection of lipoarabinomannan with plasmonic grating biosensors in clinical samples of HIV negative patients with tuberculosis. Wood A, Barizuddin S, Darr CM, Mathai CJ, Ball A, Minch K, Somoskovi A, Hamasur B, Connelly JT, Weigl B, Andama A, Cattamanchi A, Gangopadhyay K, Bok S, Gangopadhyay S. PLoS One. 2019 Mar 26;14(3):e0214161. doi: 10.1371/journal.pone.0214161. eCollection […]

Protein-surface conjugation

Forget about the EDC-NHS conjugation. Our technology makes a simple, fast and one step conjugation possible without a cumbersome process. Antibody particle conjugation can be achieved in minutes on a industrial scale.

Blood Sample Preparation

Our magnetic particle based treatment removes all the interfering antibodies from blood/serum/plasma an thus removes unspecific background. No more false positive tests in patients who recieved immunotherapy or patients with elevated levels of IgG and IgM in serum.

SpeClean

New and unique sample treatment technology (SpeClean – Specimen Cleaner) for removal of inhibitory substances present in the body fluid sample and which in effect interfere with the immunoassays used to detect the disease biomarkers. Treatment of samples with SpeClean technology results in: increased analytical sensitivity, removal of background (false positive) and additionally increases the […]

Global Good and Biopromic Partner to Co-Develop Low-Cost Diagnostic to Detect Tuberculosis

Biopromic AB announced a technology co-development and license agreement with The Global Good Fund, managed by Intellectual Ventures, to develop a rapid, low-cost and high-sensitivity diagnostic test for the detection of tuberculosis (TB), one of the leading causes of death worldwide. The partnership will combine Global Good’s assay platform with Biopromic’s proprietary technologies in sample […]